Latest SEC Filings

Allarity Therapeutics, Inc.Allarity Therapeutics Reports $3.4 Million Net Loss in Q2 2026, Revenue Increases to $25,000

GT Biopharma, Inc.GT Biopharma Reports $4.5 Million Net Loss in Q2 2026, Sees Increase in Operating Expenses

Leatt CorpLeatt Corporation Reports Modest Revenue Growth and Strategic Acquisition in Q2 2026

Clene Inc.Clene Inc. Reports Q2 2026 Revenue Increase to $90,000 Amid Continued Losses

Zapata Quantum, Inc.Zapata Quantum Reports No Revenue and Increased Losses in Latest Financial Filing

Quantum Cyber N.V.Quantum Cyber N.V. Reports No Revenue and Increased Losses Amid Strategic Transition

1847 Holdings LLC1847 Holdings Reports Significant Decline in Revenue and Net Loss for Q2 2026

Genvor IncGenvor Reports No Revenue, Increased Losses, and Strategic Developments in Latest 10-Q Filing

VerifyMe, Inc.VerifyMe Reports 58% Revenue Decline and Net Loss in Q2 2026 Amid Merger Plans

TuHURA Biosciences, Inc./NVTuHURA Biosciences Reports $9.2 Million Net Loss for Q2 2026, Sees Increase in R&D Expenses

Lightwave Logic, Inc.Lightwave Logic Reports $6.6 Million Net Loss in Q2 2026, Increases R&D Spending

PMV Pharmaceuticals, Inc.PMV Pharmaceuticals Reports $18.1 Million Net Loss in Q2 2026, Decreasing from Previous Year

Nuvera Communications, Inc.Nuvera Communications Reports Q2 2026 Revenue of $17.7M, Net Loss Improves

First Carolina Financial Services, Inc.First Carolina Financial Services Reports $5.1 Million Net Income for Q2 2026

AirJoule Technologies Corp.AirJoule Technologies Reports $8.5 Million Net Loss in Q2 2026 Amid Financial Challenges

LanzaTech Global, Inc.LanzaTech Reports $184.3 Million Net Income in Q2 2026, Significant Turnaround from Loss

GALECTIN THERAPEUTICS INCGalectin Therapeutics Reports $9.175 Million Net Loss in Q2 2026, Focuses on Belapectin Development

NEXPOINT DIVERSIFIED REAL ESTATE TRUSTNexPoint Diversified Real Estate Trust Reports Q2 2026 Financial Results with Revenue Decline and Net Income Turnaround

HawkEye 360, Inc.HawkEye 360 Reports 87% Revenue Growth to $49.8 Million Despite Net Loss

GRI BIO, Inc.GRI Bio Reports Q2 2026 Financial Results with Reduced Net Loss and Increased Cash Reserves

CREATIVE REALITIES, INC.Creative Realities Reports 65% Revenue Growth to $21.5 Million, Net Loss Widens

Teamshares IncTeamshares Inc. Reports 20% Revenue Growth and Net Income Turnaround in Q2 2026

Lantern Pharma Inc.Lantern Pharma Reports $10.4 Million Net Loss for First Half of 2026

ZW Data Action Technologies Inc.ZW Data Action Technologies Reports Revenue Decline and Improved Net Loss for First Half of 2026

Neumora Therapeutics, Inc.Neumora Therapeutics Reports $43.1 Million Net Loss in Q2 2026, Decreasing from Previous Year